Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06411080
Other study ID # 2025-12250
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2024
Est. completion date September 1, 2026

Study information

Verified date May 2024
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact William Beaubien-Souligny, MD PhD
Phone 5148908000
Email william.beaubien-souligny@umontral.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fluid expansion with isotonic crystalloids is a first-line intervention in the treatment of patients with acute kidney injury (AKI). While it is generally accepted that the timely correction of kidney hypoperfusion will minimize the extent of injury as well as potentially facilitate recovery, there are potential harms involved in indiscriminate administration of intravenous fluids. Although anticipating fluid tolerance is part of the clinical evaluation of a patient for whom intravenous fluid therapy is considered, it has been suggested that using Point-Of-Care ultrasound (POCUS) may enable the early identification of patients with a high-risk of congestive complications and guide clinical decisions with greater precision[1]. However, it has not been shown that providing this information in the context of AKI result in a change in management or a prevention of complications. This single-center pilot randomized controlled trial aim to determine the feasibility of comparing a management including a POCUS evaluation of fluid tolerance to usual care in non-critically ill patients with AKI. In the intervention group, a POCUS evaluation will be performed and interpreted by experienced staff producing a report that will be presented to the attending care team. This assessment will be repeated 48-72 hours later. The primary aim of the study will be to establish the feasibility of this intervention. Secondary objectives will include determining the difference between the intervention arm and the control arm in relationship with fluid administration, diuretic use, evolution of kidney function, and intensification of care.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date September 1, 2026
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults = 18 year-old 2. Admitted to the hospital 3. Acute kidney injury defined by the KDIGO criteria[48] 4. Fluid expansion is considered by attending nephrologist or already ongoing Exclusion Criteria: 1. Admitted to the intensive care unit 2. Known stage 5 chronic kidney disease according to the KDIGO classification receiving renal replacement therapy or not. 3. Renal replacement therapy for AKI has been initiated or is planned within 24 hours

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Ultrasound evaluation of fluid tolerance
Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Kidney and liver stiffness median values of shear-wave propagation speed in m/sec obtained by shear-wave elastography assessment of the respective organ parenchyma. 5 days
Other Fluid responsiveness increase of 7 msec or more in the corrected carotid flow time following a passive leg raising manoeuvre.[47] (Binary - Yes/no) 5 days
Other The perceived usefulness of the ultrasound report be reported on a sliding scale from 0 to 10. A score of 0 will mean that the information is considered useless while a score of 10 will mean that the information provided had a critical impact of clinical management. (Continuous - points) 5 days
Primary Protocol adherence : Ultrasound assessments were performed as planned and the reports were generated and transmitted to the attending care team in the prespecified periods. 30 days
Secondary Cumulative intravenous fluid Amount of fluid in mL received 5 days
Secondary Diuretic use defined as the use of loop diuretics 5 days
Secondary Kinetic estimated glomerular filtration rate (KeGFR) Kinetic estimated glomerular filtration rate (KeGFR) will be derived from serial measurements in serum creatinine 5 days
Secondary Progression to a higher stage of AKI Progression to a higher stage of AKI will be defined as any increase in the KDIGO staging criteria of increase in creatinine:
Operational definition: Increase in at least one level compared to baseline AKI staging during the first 5 days:
Stage 1: Increase in serum creatinine by =26.5 µmol/L within 48 hours or increase to 1.5-1.9 times baseline within the last 7 days.
Stage 2: Increase in serum creatinine to 2.0-2.9 times baseline. Stage 3: Increase in serum creatinine to =3.0 times baseline or increase to =354 µmol/L, Stage 3D: Initiation of renal replacement therapy.
5 days
Secondary Death or escalation of care composite endpoint defined as the occurrence of at least one of the following events occurring within 10 days after randomization: death from any cause, intervention of the rapid response team, admission to the intensive care unit, initiation of non-invasive positive pressure ventilation, initiation of renal replacement therapy. (Binary - Yes/no) 10 days
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A